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Abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) 
clearly inhibit the synthesis and release of prostaglandins. 
However, these actions are not sufficient to explain all the 
anti-inflammatory effects of these drugs. Recently, it has been 
shown that aspirin and sodium salicylate inhibit the activation of 
the transcription factor NF-gB. Group II phospholipase A2 
(sPLA2) is expressed in rat glomerular mesangial cells upon 
exposure to the inflammatory cytokine interleukin-113 (IL-1I]) 
and this induction is attenuated by the NF-r,B inhibitor 
pyrrolidine dithiocarbamate (PDTC). We now report that aspirin 
inhibits the IL-l~induced sPLA2 activity in rat mesangial ceils 
in a dose-dependent manner. The ICso value of aspirin for sPLA2 
inhibition was 6.5 mM. This decrease in sPLA2 activity was not 
due to direct inhibition of enzymatic activity but rather to the 
fact that aspirin inhibits the expression of IL-l~-induced sPLA2 
protein and mRNA. Furthermore, by electrophoretic mobility 
shift analysis we demonstrate reduced DNA binding of the 
nuclear factor r,B, an essential component of the IL-113- 
dependent upregulation of sPLA2 gene transcription, after 
treatment of the cells with aspirin. The study described in this 
report indicates that the inhibition of sPLA2 expression as 
induced by pro-inflammatory cytokines potentially represents an 
additional mechanism of action for aspirin. 
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1. Introduction 
Phospholipase A2 (PLA2) is thought to play an important 
role in the process of inflammation. Mammalian 14 kDA 
group II PLA2 is found in soluble form at inflammatory sites 
such as peritoneal exudates [1] and synovial fluid in rheuma- 
toid arthritis [2,3] and is believed to play an important role in 
the initiation and propagation of inflammatory processes [4]. 
High doses of aspirin and other nonsteroidal anti-inflam- 
matory drugs (NSAIDs) are particularly effective in the treat- 
ment of inflammatory diseases [5]. The mechanisms of action 
of NSAIDs are explained mainly by their ability to inhibit the 
cyclooxygenase (COX) reaction [6-8]. COX exists in at least 
two isoforms, of which COX-1 is expressed constitutively and 
COX-2 is expressed only following cell activation. COX-2 is 
induced in a number of cells by pro-infammatory stimuli and 
cytokines [9] and it is most likely that the anti-inflammatory 
actions of aspirin are due to the inhibition of COX-2. How- 
ever, aspirin is over 100-fold more active towards COX-1 than 
towards COX-2 [6]. Furthermore, low doses of aspirin and 
other NSAIDs inhibit the synthesis of prostaglandin vitro 
[6,10] and in vivo [11] but much higher doses are required for 
an anti-inflammatory effect in vivo [12,13]. Another member 
of the NSAIDs, sodium salicylate, is an ineffective COX in- 
hibitor but is still able to reduce inflammation at doses com- 
parable to those of aspirin [10,14,15]. So, the inhibition of 
COX does not appear to be sufficient o explain all the anti- 
inflammatory effects of aspirin. 
Recently, it has been reported that aspirin and sodium sal- 
icylate inhibit NF-~cB activation presumably by inhibiting the 
phosphorylation a d degradation of its inhibitor, I~B, in cul- 
tured human Jurkat cells and mouse PD31 pre-B cells [16]. 
Numerous agents which can cause activation of NF-~cB by 
release from I~cB have been identified; these include the in- 
flammatory cytokines interleukin-113 (IL-113) and tumor necro- 
sis factor c~ (TNF) [17]. 
IL-113 and TNF have been shown to induce the synthesis 
and secretion of non-pancreatic group II PLA2, also referred 
to as sPLA2, in many cell types including rat mesangial cells 
[18,19]. The increase in sPLA2 activity and synthesis i accom- 
panied by an increase in sPLA2 mRNA levels [20,21]. Re- 
cently, it has been shown that pyrrolidine dithiocarbamate 
(PDTC), an antioxidant acting as a potent inhibitor of nuclear 
factor NF-~B activation, inhibits the increase in sPLA2 
mRNA steady state levels in response to IL-113 [22]. These 
data suggest hat NF-~B activation is an essential component 
in the cytokine signaling pathway responsible for sPLA2 gene 
regulation. 
In view of the above findings we investigated whether aspir- 
in affected the IL-113-induced sPLA2 activity in rat renal me- 
sangial cells. Aspirin was tested for its capacity to inhibit both 
sPLA2 activity and gene expression. We report that aspirin 
inhibits sPLA2 expression and activity in rat mesangial cells 
stimulated with IL-113, although at therapeutic concentrations 
the inhibition is only partial. In addition, we show with elec- 
trophoretic mobility shift analysis that these results can be 
explained by the observed inhibition by aspirin of the IL- 
113-induced activation of NF-~cB. We therefore conclude that 
inhibition of sPLA2 expression and activity may represent 
another mechanism of action of aspirin and that at least 
part of the anti-inflammatory action of this drug in chronic 
inflammatory states may be due to inhibition of sPLA2 syn- 
thesis. 
*Corresponding author. Fax: (31) (30) 2537990. 
Abbreviations: IL-l13, interleukin-l~; sPLA2, secretory phospholipase 
A2 ; NF-~B, nuclear factor ~cB; NSAIDs, nonsteroidal nti-inflamma- 
tory drugs 
2. Materials and methods 
2.1. Materials 
Recombinant IL-I[3 was prepared by the Biotechnology Depart- 
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ment of Ciba Geigy Ltd., Basel, Switzerland. Forskolin and fatty 
acid-free bovine serum albumin (BSA) were obtained from Sigma, 
St. Louis, MO, USA. Aspirin was purchased from Janssen Chimica, 
Beerse, Belgium. Nitrocellulose and Nytran nylon membranes were 
obtained from Schleicher and Schuell, Dassel, Germany. Double- 
stranded poly(dI-dC) was a product from Pharmacia Biotech, Roo- 
sendaal, The Netherlands. NF-~B and SP-I consensus oligonucleo- 
tides (1.75 pmol/lal), T4 polynucleotide kinase (PNK) (5-10 U/lal) 
and T4 PNK 10X buffer were part of a Gel Shift Assay System 
from Promega Corporation BNL, Leiden, The Netherlands. 
2.2. Cell culture and incubation 
Cultivation and characterization f rat mesangial cells were per- 
formed as described previously [23]. For the experiments passages 
8-20 were used. Confluent mesangial cells cultured in 75 cm 2 flasks 
were rinsed once with PBS and incubated with 10 ml serum-free 
DMEM containing 0.1 mg/ml fatty acid-free bovine serum albumin 
(Sigma) and treated with aspirin and immediately stimulated with IL- 
11] for 20 h. Solutions containing aspirin were brought o pH 7.4 with 
concentrated NaOH prior to use [24]. 
2.3. PLA2 assay 
PLAe activity was assayed using 0.2 mM sn-2-1abeled [l- 
~4C]linoleoylphosphatidylethanolamine (sp cific activity 3000 dpm/ 
nmol) in 0.2 ml of 0.1 M Tris/HCl, pH 8.5, in the presence of 10 
mM CaCI2. Reactions were stopped after 30 min and the liberated 
14C-labeled fatty acids were extracted by a modified Dole extraction 
procedure [25]. The substrate 1-acyl-2[1-14C]linoleoylphosphatidyl - 
ethanolamine was prepared as described earlier [25]. 
2.4. Immunoblotting 
Cells were washed once with PBS, scraped in homogenization buffer 
(50 mM HEPES pH 7.4, 0.25 M sucrose, 1 mM EDTA, 1 mM 
EGTA, 10 mM leupeptin, 0.1 mM pepstatin and 0.15 mM PMSF) 
and homogenized through a 27 G needle. Western blot analysis of 
protein extracts from mesangial cells and culture media using a mono- 
clonal antibody specific for sPLA2 was performed as previously de- 
scribed [19,21]. 
2.5. Northern blot analysis 
Total mesangial cell RNA was extracted using the guanidinium 
thiocyanate/phenol/chloroform method and blotted on Nytran nylon 
membrane as described before [21]. The RNA was fixed to the mem- 
brane by 3 min treatment in a microwave oven at full setting (650 W) 
[26]. Prehybridization, hybridization and autoradiography were per- 
formed as previously described [21]. The ribosomal RNA was stained 
on the filters with methylene blue [27] in order to asses equal RNA 
loading and transfer. 
2.6. Assessment of aspirin cytotoxicity 
The cytotoxic effect of aspirin on rat mesangial cells was assessed 
by lactate dehydrogenase (LDH) release according to the method 
described by Moldeus et al. [28]. LDH was measured in cell culture 
supernatants after 20 h incubation in the presence or absence of IL-I~ 
and different concentrations of aspirin. A separate sample was treated 
with 1% Triton X-100 for 30 min at 23°C, for the measurement of
total LDH activity. 
2. 7. Nuclear extract preparation 
Nuclear extracts from cultured mesangial cells were isolated by a 
rapid method modified from Dignam et al. [29,30]. For the prepara- 
tion of nuclei, cells from confluent 75 cm 2 flasks were gently washed 
twice with ice-cold PBS and scraped off in 1 ml ice-cold hypotonic 
buffer (buffer A: 10 mM HEPES pH 7.9; 10 mM KCI; 0.1 mM 
EDTA; 0.1 mM EGTA; and freshly added 1 mM DTT and 0.5 
mM PMSF) [31]. The cells were allowed to swell on ice for 15 min 
after which a 10% solution of Nonidet P-40 was added (0.1% final 
concentration). Thereafter, the cells were vigorously vortexed for 10 s 
and the nuclei were pelleted by centrifugation at 12000×g for 15 s at 
4°C. The nuclei were gently resuspended in 100 Ixl ice-cold high salt 
extraction buffer (buffer C: 20 mM HEPES pH 7.9; 0.4 M NaCI; 
1 mM EDTA; 1 mM EGTA; and freshly added 1 mM DTT and 
0.5 mM PMSF) and incubated for 20 min on ice while shaking. The 
lysates were centrifuged at 12 000 × g for 5 min at 4°C and the super- 
natants were transferred to new Eppendorf tubes and then further 
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supplemented with 0.5 mM PMSF, aliquoted and stored at -80°C. 
Between steps the samples were always kept on ice. Protein concen- 
tration was determined by the method of Bradford [32] with bovine 
serum albumin as standard. 
2.8. Electrophoretic mobility shift assay (EMSA) 
Double stranded oligonucleotides containing the NF-nB consensus 
sequence (5'-AGTTGAGGGGACTTTCCCAGGC-3'; Promega) were 
end-labelled using T4 polynucleotide kinase and [7-32P]ATP (Amer- 
sham, 3000 Ci/mmol, 10 mCi/ml). 10 ~tg of nuclear protein was pre- 
incubated for 10 min at RT in a 19 111 binding mixture containing 
binding buffer (4% Ficoll; 20 mM HEPES pH 7.9; 50 mM KCI; 
1 mM EDTA; 1 mM DTT; 0.25 mg/ml BSA), 2 I.tg poly(dI-dC) and 
0.3 /.tg herring sperm DNA. Thereafter, binding reactions were per- 
formed for 25 min on ice with 200 nCi of radiolabelled oligonucleotide 
in a final volume of 21 ~1. Nucleoprotein-oligonucleotide complexes 
were resolved by electrophoresis on a 4% acrylamide (acrylamide/ 
bisacrylamide, 30:1) gel at 100 V for 3 h. Prior to sample loading, 
the gel was run for 1 h at 100 V [33]. After electrophoresis, the gel was 
exposed to an X-ray film for 12-24 h at -80°C. Specificity of binding 
was determined by prior addition of a 10-fold excess of non-labelled 
competitor (NF-nB) or non-competitor (SP-1 ; 5'-ATTCGATCGGG- 
GCGGGGCGAGC-3'; Promega) consensus oligonucleotide. 
3. Results 
3.1. Effect of  aspirin on IL-l~-indueed sPLA2 activity 
In mesangial cells the pro-inflammatory c tokine IL-113 can 
induce the synthesis and secretion of sPLA2 [19]. Previous 
work has suggested that NF-~cB activation is an essential com- 
ponent in the cytokine signaling pathway responsible for 
group II PLA2 gene regulation in rat mesangial cells [22]. In 
addition it has been shown that the anti-inflammatory drug 
aspirin can inhibit the activation of NF-KB [16]. In view of 
these facts we examined the effect of aspirin on IL-l~-induced 
sPLA2 activity. Rat mesangial cells were activated with IL- I~ 
to induce sPLA2 and simultaneously incubated with vehicle or 
different concentrations of aspirin (2-25 mM). In Fig. 1 a 
concentration-dependent inhibition of sPLA2 activity by as- 
pirin is shown in both cells and culture media. Suprapharma- 
cological concentrations of aspirin (5 and 10 mM) decreased 
sPLA2 activity to 54+ 10%o and 34+ 15% in the media, and 
61 + 17% and 38 + 13% in the cells, respectively, compared to 
total sPLA2 activity in IL-113-stimulated cells. At a concentra- 
tion of 15 mM of aspirin the activity completely decreased to 
control level. At pharmacological concentrations of aspirin (2 
mM) a decrease in sPLA2 activity of approximately 14% was 
found in both cells and culture medium. 
The inhibition of sPLAz activity occurred at drug concen- 
trations that were not toxic to the cells as assessed by LDH 
release in the culture medium. The percent of total cellular 
LDH released in control cultures activated with IL-113 alone 
was less than 7% as measured in three independent experi- 
ments. No appreciable cytotoxicity (LDH release equivalent 
to control) was observed with aspirin at all concentrations 
tested (results not shown). Thus, it can be concluded that 
cytotoxicity did not account for the inhibitory effects on 
sPLA2 activity. 
3.2. Effect of  aspirin on sPLA2 protein levels 
It is known that aspirin inhibits COX activity by acetylating 
the enzyme in an irreversible way. Inhibition of IL- l- induced 
COX expression by aspirin in cultured endothelial cells has 
also been reported [34]. This raised the question how aspirin 
inhibits IL-l~-induced sPLA2 activity. Aspirin may decrease 
the expression of sPLA2 protein and, therefore, decrease the 
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Fig. 1. Effect of aspirin on IL-ll3-induced sPLA2 activity. Rat me- 
sangial cells were treated with the indicated concentrations of aspir- 
in (ASP) and immediately activated by addition of IL-II3. The 
sPLA2 activity was determined 20 h later in the culture media and 
cell homogenates. Results are means _+ S.E. (n = 5). The 100% values 
for IL-113-stimulated cells amounted to 1.63 + 0.59 nmol/min/ml and 
1.52-+ 0.59 nmol/min/mg protein for media and cells, respectively. 
specific activity of the enzyme or it may decrease only the 
specific activity of the enzyme without influencing the expres- 
sion of sPLA2 protein levels. To differentiate between these 
possibilities we analyzed by immunoblotting sPLA2 protein 
expression in IL-1I]- and aspirin-treated cells. Fig. 2 shows a 
dose-dependent decrease in sPLA2 expression in cells and 
medium treated with different concentrations of aspirin which 
is already clearly visible at 2 mM aspirin. Aspirin, at concen- 
trations up to 20 raM, did not affect sPLA2 activity measure- 
ments (data not shown). From these results it can be con- 
cluded that inhibition of sPLA2 protein expression accounts 
for the decrease in sPLA2 activity in cells treated with aspirin. 
3.3. Effect of aspirin on expression of  IL-l~-induced sPLA2 
mRNA levels 
Additional studies were performed to evaluate whether the 
effect on sPLA2 activity and protein levels was due to altered 
sPLA2 gene expression. We addressed this question because 
down-regulation of sPLA2 mRNA levels is not always found 
in experiments where IL-l~-induced sPLA2 protein levels are 
decreased, as we showed previously for the inhibition of 
sPLA2 expression by dexamethasone in rat mesangial cells 
[21]. In order to determine whether the inhibition of IL-I~- 
dependent stimulation of sPLA2 expression by aspirin was 
due to down-regulation of sPLA2 steady state mRNA levels 
we performed Northern blot analyses. Fig, 3 shows a clear 
decrease in sPLA2 mRNA levels by aspirin. This decrease is in 
parallel with the reduction in IL-l~-induced sPLA2 activity 
(Fig. 1) and protein levels (Fig. 2) by aspirin. 
3.4. Effect of aspirin on NF-r,B activation 
Previously it has been reported that NF-~B is an essential 
transcription factor mediating sPLA2 gene activation in re- 
sponse to IL-113 [22]. In addition, it has been reported that 
aspirin inhibits the activation of NF-~:B [16] by preventing the 
degradation of the NF-~cB inhibitor, I~B. This led us to in- 
vestigate the effect of aspirin on the activation of NF-~cB by 
IL-113 in mesangial cells. To detect NF-~B binding activity we 
performed EMSAs. In control cells hardly any complex was 
observed (Fig. 4, left, lane 2), whereas IL-II] elicited a sub- 
stantial rise in NF-~cB DNA binding activity (Fig. 4, left, lane 
3). Following IL-113 treatment two NF-~B DNA-protein com- 
plexes were identified in the nuclear extract of cultured me- 
sangial cells. The slower migrating complex comprises the 
p65/p50 heterodimer of NF-~B and the faster migrating com- 
plex is likely to represent the p50/p50 homodimer which has 
been previously demonstrated to be present in the extracts of 
mesangial cells [35]. After simultaneous addition of IL-I~ and 
aspirin neither the p65-containing DNA-protein complex nor 
the p50/p50-1ike complex was detectable, indicating that aspir- 
in abolished lL-113-mediated activation of NF-~cB (Fig. 4, left, 
lane 4). Competition analysis further determined the specifi- 
city of the DNA-protein complexes observed. As shown in 
Fig. 4, right, lane 2, inclusion of a 10-fold excess of unlabelled 
double stranded NF-~B oligonucleotides in the DNA binding 
reaction effectively abolished the IL-113-induced formation of 
specific DNA-protein complexes. When a 10-fold excess of 
SP-1 consensus oligonucleotides was added to the binding 
reaction the DNA-protein complex formed was unaffected 
thereby assessing the specificity of the complexes een (Fig. 
4, right, lane 3). 
4. Discussion 
NSAIDs are widely used in the treatment of pain and in- 
flammation associated with acute injury or chronic diseases. 
The action of aspirin and other NSAIDs on the COX is well 
known. However, this action is not likely to be solely respon- 
sible for the total anti-inflammatory effects of these drugs 
because compared to doses that inhibit prostaglandin syn- 
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Fig. 2. Effect of aspirin on IL-l[~-induced sPLA2 protein levels in cells and culture medium. Rat mesangial cells were treated with the indicated 
concentrations of aspirin (ASP) and immediately activated by addition of IL-113 (1 nM). Thereafter, aliquots of 800 /al of the culture superna- 
tants or 20 ~tg of cellular protein were used for Western blotting and sPLA2 immunostaining. 
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thesis in vivo [11], much higher doses are needed in vivo for 
an anti-inflammatory effect [12,13]. 
The involvement of sPLAz in the pathophysiology of var- 
ious diseases has been well documented, sPLA2 can release a 
fatty acid, often arachidonic acid, from the sn-2 position of 
membrane phospholipids with concomitant production of a 
lysophospholipid. The free arachidonic acid serves as precur- 
sor for the COX pathway producing thromboxanes, prosta- 
cyclins and other prostaglandins, but it also serves as a sub- 
strate for the 5-1ipoxygenase pathway producing leukotrienes. 
Alkyl lysophosphatidylcholine is converted to platelet activat- 
ing factor (PAF), another important lipid mediator. Thus, if 
sPLA2 is inhibited, in principle all three inflammatory path- 
ways discussed above can be blocked. In addition, it has re- 
cently been shown that aspirin can inhibit NF-~cB [16] and this 
transcription factor is involved in the activation of sPLA2 by 
pro-inflammatory c tokines in rat mesangial cells [22]. Thus, 
sPLA2 expression is a likely candidate for the additional ac- 
tion of NSAIDs. 
In the present study we showed that aspirin can inhibit the 
activity of IL-113-induced sPLA2 in a dose-dependent manner 
(Fig. 1). Western blot analysis revealed that the decrease in 
sPLA2 activity occurs in parallel with the decrease in sPLAz 
protein levels (Fig. 2). Thus, the decrease in sPLA2 protein 
level by aspirin accounts for inhibition of sPLA2 activity. This 
finding is in agreement with a recent report in which the 
authors howed that aspirin had no direct effect on the enzy- 
matic activity of group II PLAz as measured in an in vitro 
assay system [36]. Northern blot analysis of rat mesangial cells 
treated with aspirin showed suppression of sPLA2 mRNA 
induction by IL-II3 (Fig. 3). The fact that the transcription 
of IL-l[~-induced sPLA2 mRNA is inhibited by aspirin is ex- 
plained most easily by the hypothesis that also in rat mesan- 
gial cells activation of NF-~B is inhibited by aspirin. By EM- 
SAs we established that IL-113-induced NF-KB-activation is
indeed inhibited in rat mesangial cells. The results obtained 
show that the IL-l[3-activated DNA binding activity of NF- 
~cB is drastically reduced under the action of aspirin (Fig. 4, 
left, lanes 3 and 4). Competition analysis further determined 
the specificity of the DNA-protein complexes observed (Fig. 
4, right). Tile inhibition of DNA binding activity of NF-~B 
may be the key step in the suppression of the cytokine induced 
sPLA2 expression by aspirin in rat. mesangial cells. 
The action of aspirin on the induction of sPLA2 by IL-l[3 is 
consistent with results from a recent study from Kopp and 
Ghosh [16]. They showed that aspirin (3 mM) and sodium 
salicylate (5 mM) inhibit NF-~B-dependent transcription, 
sPLA 2 "*  
28  S "*  
IL-113 (1 nM) + + + + + 
ASP (mM) 0 0 5 10 15 25 
Fig. 3. Effect of aspirin on expression of IL-[3-induced sPLA~ 
mRNA in rat mesangial cells. Indicated concentrations of aspirin 
were added to the culture medium of rat mesangial cells followed 
by the induction of sPLA2 by adding IL-1[3 (1 nM) to each flask 
for 20 h. After the end of this period, total RNA was isolated and 
20 lag was used for Northern blot hybridizations for sPLA2 mRNA. 
RNA loading and tranfer was assessed by staining of 28S RNA 
with methylene blue. 
~ cL 
< .'= E 
~- + g o o 
o ~=-  ,,-, ~- ? 
0.5 -  .5 o o 
¢-  0 - -  - -  - -  0 e"  
~E- pSO/p65 
pSO/pSO p5o/p65 
. p50ip5o 
1 2 3 4 1 2 3 
Fig. 4. Effect of aspirin on IL-l~-induced NF-~cB activation. Left: 
Mesangial cells were stimulated with vehicle (con, lane 2), IL-11] (1 
nM, lane 3), IL-I~ (1 nM) plus aspirin (15 mM, lane 4) for 20 h. 
Nuclear extracts were prepared as described in Section 2 and equal 
amounts were incubated with a radiolabelled NF-KB oligonucleotide 
probe. No nuclear protein was added to the negative control (lane 
1). DNA-protein complexes were analyzed on a 4% polyacrylamide 
gel. The position of p50/65 heterodimer and p50/p50 homodimer is
shown. Right: Specificity of the DNA-protein complexes. Nuclear 
proteins were incubated in the presence of a 10-fold excess of either 
unlabelled NF-kB (competitor, lane 2) or of SP-I (non-competitor, 
lane 3) consensus oligonucleotides. 
using sensitive assays based on plasmids containing two 
IgK-~B sites driving a luciferase reporter gene. However, the 
same concentrations of these drugs had no significant effect on 
NF-~zB activation as examined by mobility shift analysis in 
which case effects on NF-~B were only observed at relatively 
high concentrations of 5-20 mM [16]. According to the 
authors mM aspirin concentrations may be maintained in 
the plasma for treatment of chronic inflammatory states like 
arthritis [37]. 
Plasma and synovial fluid concentrations of aspirin and 
sodium salicylate in rheumatics are close to those shown to 
be inhibitory for NF-KB activation by Kopp and Gosh [16] 
and for sPLA2 induction in the present study. However, the 
relevance of comparing the effectiveness of drug levels in tis- 
sue culture studies in vitro with those in plasma in vivo is 
questionable. During inflammation, capillary damage leading 
to extravasation f protein-bound NSAIDs and an acidic en- 
vironment of cells can enhance concentration and uptake of 
acidic NSAIDs [38] in inflamed joint tissues. Thus, the con- 
centration of NSAIDs may be higher in inflamed tissue than 
in plasma making it difficult to compare these concentrations 
with those used in cell culture studies. 
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In summary, the inhibitory effects of aspirin reported herein 
lend further support to the conclusion that IL-113-induced 
sPLA2 expression is mediated by NF-~rB activation as pre- 
viously noticed from the inhibition by pyrrolidine dithiocar- 
bamate [22]. It is clear that aspirin does not inhibit sPLA2 
expression completely at pharmacological concentrations. 
However, partial suppression of cytokine inducible sPLA2 
may be sufficient to mitigate an inflammatory response as 
has been proposed for the inhibition of iNOS by aspirin 
[39]. The partial inhibition of IL-ll3-induced sPLA2 expression 
may represent an additional mechanism of action for aspirin 
and perhaps also other aspirin-like drugs. The anti-inflamma- 
tory action of aspirin-like drugs may then be due not only to 
inhibition of prostaglandin synthesis but also to the suppres- 
sion of inducible sPLA2 gene expression. 
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